Priyanshu Chandra
Name of Student ………………………………………………………
92
Roll No……………………………………………………………………..
03-02-2025
Date : ……………………………………………………………………….
Pharmacovigilance Quiz
Multiple Choice Questions (MCQs):
1. What is pharmacovigilance? 6. What should a Doctor/Pharmacist/Nurse do if
A. The study of pharmacokinetics and an ADR is suspected?
pharmacodynamics A. Discontinue the medication without
B. The process of discovering new drugs consulting anyone
C. The science of detecting, assessing, and B. Report the ADR to a pharmacovigilance
preventing adverse drug reactions centre
D. The study of drug interactions C. Ignore the ADR unless it is life-threatening
2. An adverse drug reaction (ADR) is defined as: D. Prescribe a different drug
A. An intentional overdose of a drug 7. What is the role of the nurse in
B. Any harmful and unintended response to a pharmacovigilance?
medication administered at normal doses A. Administering medication only
C. A beneficial side effect of a drug B. Monitoring and documenting adverse
D. A natural progression of the disease reactions, and reporting them
3. Who is responsible for reporting adverse drug C. Prescribing medications
reactions? D. None of the above
A. Only doctors 8. Pharmacovigilance Programme of India
B. Only pharmacists started in which year?
C. Only nurses A. 2015
D. All healthcare professionals, including B. 2010
doctors, nurses, and pharmacists C. 2008
4. The primary goal of pharmacovigilance is to: D. 2007
9. Suspected ADRs can be reported for
A. Promote the sale of safer medications
A. Allopathic Drugs
B. Prevent medication errors in hospitals
B. Homeopathic Medicines
C. Ensure the safety and well-being of patients C. Traditional Medicines
by monitoring drug safety D. All the Above
D. Evaluate the cost-effectiveness of 10. While filling ADR reporting form, which of the
medications following information is kept confidential
5. Which phase of a clinical trial primarily A. Patient’s & Reporter’s information
focuses on drug safety monitoring? B. Manufacturer Details
A. Phase I C. Adverse Drug Reactions
B. Phase II D. All the Above
C. Phase III
D. Phase IV (Post-marketing surveillance)